The pooled data from two studies involving 176 advanced cancer patients showed that CD133 positive expression was associated with a worse cancer-specific survival (CSS) (HR = 3.70, 95% CI = 1.09-12.54, P = 0.036) (Figure 2). This evidence concerns the gene PROM1 and cancer.